News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
News FDA clears first genetic hearing loss gene therapy Regeneron's Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
